Zumutor Biologics, a company that is working on to develop immunotherapies to fight cancer, has now secured $4 million led by the venture capital firm Bharat Innovation Fund. Some of the existing investor Accel participated in the round.
The latest funding takes the total capital secured by the company, which has its operations in research and development, to $40 million, said the announcement.
Dubbing the latest infusion a Series A2 round, founder and CEO Kavitha Iyer Rodrigues, said in a statement, “Our first-in-class lead molecule, ZM 008 has made industry-validated progress and is poised for an IND filing with phase 1a/1b clinical trials likely to commence end 2020. The Series A 2 funding will enable pivotal milestones in development stages.”
“We are excited to back a world-class scientific team, a second-time entrepreneur and a company developing immuno-therapeutic products using their proprietary platforms. The strong pipeline that Zumutor has developed combined with a relatively differentiated NK cell approach could lead to breakthrough treatments for multiple cancers,” Ashwin Raguraman, founding partner of Bharat Innovation Fund said.
